Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17320988 | 0.84 | ADORA2A (0.34) | CNR1CNR2AURKARPS6KB1ADORA2A | |
| SCHEMBL15553669 | 0.81 | AURKA (0.33) | CNR1CNR2AURKARPS6KB1ADORA2A | |
| SCHEMBL12935855 | 0.79 | ADORA2A (0.36) | CNR1CNR2AURKARPS6KB1ADORA2A | |
| SCHEMBL15898809 | 0.79 | MAPK1 (0.34) | CNR1CNR2 | |
| SCHEMBL23399834 | 0.78 | CNR1 (0.34) | CNR1CNR2AURKARPS6KB1ADORA2A | |
| SCHEMBL12740612 | 0.78 | BCHE (0.39) | CNR1CNR2POLBMAPTGAA | |
| SCHEMBL12102938 | 0.78 | POLB (0.42) | AURKARPS6KB1ADORA2AADORA2BPOLB | |
| SCHEMBL23559674 | 0.77 | CNR1 (0.32) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL2737300 | 0.76 | GAA (0.46) | AURKARPS6KB1ADORA2AADORA2BPOLB | |
| SCHEMBL1292978 | 0.72 | ADORA2A (0.42) | ADORA2AADORA2BPOLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CNR1 269/4885CNR2 590/4885AURKA 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.